{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T06:14:36Z","timestamp":1772259276642,"version":"3.50.1"},"publisher-location":"Cham","reference-count":119,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030963750","type":"print"},{"value":"9783030963767","type":"electronic"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1007\/978-3-030-96376-7_11","type":"book-chapter","created":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T09:13:39Z","timestamp":1652346819000},"page":"287-315","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Development and Therapeutic Applications of Bispecific Antibodies for Hematologic Malignancies"],"prefix":"10.1007","author":[{"given":"Priya","family":"Hays","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,5,13]]},"reference":[{"key":"11_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40364-021-00294-9","volume":"9","author":"S Zhou","year":"2021","unstructured":"Zhou S, Liu M, Ren F, Meng X, Yu J (2021) The landscape of bispecific T cell engager in cancer treatment. Biomarker Res 9:38","journal-title":"Biomarker Res"},{"key":"11_CR2","doi-asserted-by":"publisher","first-page":"3111","DOI":"10.1007\/s00432-020-03404-6","volume":"146","author":"S Huang","year":"2020","unstructured":"Huang S, van Duijnhoven SMJ, Sijtx AJA, van Elsas A (2020) Bispecific antibodies targeting dual tumor-associated antigens in cancer therapy. J Cancer Res Clin Oncol 146:3111\u20133122","journal-title":"J Cancer Res Clin Oncol"},{"key":"11_CR3","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1007\/s00277-020-04221-0","volume":"999","author":"A Viardot","year":"2020","unstructured":"Viardot A, Locatelli F, Stieglmaier J, Zaman F, Jabbour E (2020) Concepts in immune-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies. Ann Hematol 999:2215\u20132229","journal-title":"Ann Hematol"},{"key":"11_CR4","doi-asserted-by":"crossref","unstructured":"Lejeune M, Cem Kose M, Duray E, Einsele H, Beguin Y, Caers J (2020) Bispecific, T-cell recruiting antibodies in B-cell malignancies. Front Immunol 11(762)","DOI":"10.3389\/fimmu.2020.00762"},{"key":"11_CR5","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40264-018-0760-1","volume":"42","author":"A Stein","year":"2019","unstructured":"Stein A, Franklin JL, Chia VM, Arrindell D, Kormany W et al (2019) Benefit-risk assessment of blinatumomab in the treatment of relapsed\/refractory B-cell precursor acute lymphoblastic leukemia. Drug Saf 42:587\u2013601","journal-title":"Drug Saf"},{"key":"11_CR6","doi-asserted-by":"crossref","unstructured":"Poussin M, Sereno A, Wu X, Huang F, Manro J et al (2021) Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies. J Immunother Cancer 9:e002444","DOI":"10.1136\/jitc-2021-002444"},{"issue":"3","key":"11_CR7","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","volume":"136","author":"D Nagorsen","year":"2012","unstructured":"Nagorsen D, Kufer P, Baeuerle PA, Bargou R (2012) Blinatumomab: a historical perspective. Pharmacol Ther 136(3):334\u2013342","journal-title":"Pharmacol Ther"},{"key":"11_CR8","unstructured":"BLINCYTO\u00ae (blinatumomab) [prescribing information] (2019) Amgen, Thousand Oaks, CA"},{"issue":"11","key":"11_CR9","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N, Zettl F, Libicher M, Sayehli C, Stieglmaier J, Zhang A, Nagorsen D, Bargou RC (2016) Phase 2 study of bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B cell lymphoma. Blood 127(11):1410\u20131416","journal-title":"Blood"},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"6226","DOI":"10.1182\/blood-2012-01-400515","volume":"119","author":"M Klinger","year":"2012","unstructured":"Klinger M, Brandl C, Zugmaier G, Hijazi Y, Bargou RC, Topp MS et al (2012) Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19\/CD3-bispecific BiTE antibody blinatumomab. Blood 119:6226\u20136233","journal-title":"Blood"},{"key":"11_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1089\/scd.1.1995.4.433","volume":"4","author":"GC De Gast","year":"1995","unstructured":"De Gast GC, Van Houten AA, Haagen IA, Klein S, De Weger RA, Van Dijk A et al (1995) Clinical experience with CD13\u00a0x\u00a0CD19 bispecific antibodies in patients with B cell malignancies. J Hematother 4:433\u2013437","journal-title":"J Hematother"},{"key":"11_CR12","doi-asserted-by":"crossref","unstructured":"Kontermann RE, Brinkmann U (2015) Bispecific antibodies. Drug Discov Today 7","DOI":"10.1016\/j.drudis.2015.02.008"},{"key":"11_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","volume":"16","author":"MS Topp","year":"2015","unstructured":"Topp MS, Gokbuget N, Stein AS, Zugmaier G, O\u2019Brien S, Bargou RC et al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16:57\u201366","journal-title":"Lancet Oncol"},{"key":"11_CR14","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, Gokbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S et al (2014) Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32:4134\u20134140","journal-title":"J Clin Oncol"},{"key":"11_CR15","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1200\/JCO.2010.32.7270","volume":"29","author":"MS Topp","year":"2011","unstructured":"Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S et al (2011) Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 29:2493\u20132498","journal-title":"J Clin Oncol"},{"issue":"9","key":"11_CR16","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian H, Stein A, Gokbuget N, Fielding AK, Schuh AC et al (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836\u2013847","journal-title":"N Engl J Med"},{"issue":"17","key":"11_CR17","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa2016272","volume":"383","author":"R Foa","year":"2020","unstructured":"Foa R, Bassan R, Vitale A, Elia L, Piciocchi A (2020) Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med 383(17):1613\u20131623","journal-title":"N Engl J Med"},{"issue":"14","key":"11_CR18","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1182\/blood-2017-08-798322","volume":"131","author":"N G\u00f6kbuget","year":"2018","unstructured":"G\u00f6kbuget N, Dombret H, Bonifacio M, Reichle A, Graux C, Faul C, Diedrich H, Topp MS, Br\u00fcggemann M, Horst HA, Havelange V, Stieglmaier J, Wessels H, Haddad V, Benjamin JE, Zugmaier G, Nagorsen D, Bargou RC (2018) Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood 131(14):1522\u20131531","journal-title":"Blood"},{"key":"11_CR19","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, KelshM, Chia V, Advani A, Bassan R, Dombret H, Doubek M, Fielding AK, Giebel S, Haddad V, Hoelzer D, Holland C, Ifrah N, Katz A, Maniar T, Martinelli G, Morgades, M, O'Brien S, Ribera JM, Rowe JM, Stein A, Topp M, Wadleigh, M, Kantarjian H (2016) Blinatumomab vs historical standard therapy of adult relapsed\/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473","DOI":"10.1038\/bcj.2016.84"},{"issue":"2","key":"11_CR20","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","volume":"25","author":"EY Jen","year":"2019","unstructured":"Jen EY, Xu Q, Schetter A, Przepiorka D, Shen YL, Roscoe D, Sridhara R, Deisseroth A, Philip R, Farrell AT, Pazdur R (2019) FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease. Clin Cancer Res 25(2):473\u2013477","journal-title":"Clin Cancer Res"},{"issue":"9","key":"11_CR21","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1080\/10428194.2019.1576872","volume":"60","author":"H Dombret","year":"2019","unstructured":"Dombret H, Topp MS, Schuh AC, Wei AH, Durrant S, Bacon CL, Tran Q, Zimmerman Z, Kantarjian H (2019) Blinatumomab versus chemotherapy in first salvage or in later salvage for B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 60(9):2214\u20132222","journal-title":"Leuk Lymphoma"},{"issue":"24","key":"11_CR22","doi-asserted-by":"publisher","first-page":"5568","DOI":"10.1002\/cncr.25354","volume":"116","author":"HM Kantarjian","year":"2010","unstructured":"Kantarjian HM, Thomas D, Ravandi F, Faderl S, Jabbour E, Garcia-Manero G et al (2010) Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 116(24):5568\u20135574","journal-title":"Cancer"},{"key":"11_CR23","first-page":"1","volume":"563291","author":"KA Minson","year":"2013","unstructured":"Minson KA, Prasad P, Vear S, Borinstein S, Ho R, Domm J, Frangoul H (2013) t(17;19) in children with acute lymphocytic leukemia: a report of 3 cases and a review of the literature. Case Rep Hematol 563291:1\u20134","journal-title":"Case Rep Hematol"},{"key":"11_CR24","doi-asserted-by":"crossref","unstructured":"Jabbour EJ, Gokbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS (2019) Transplantation in adults with relapsed\/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Cancer 125(23):4181\u20134192","DOI":"10.1002\/cncr.32335"},{"issue":"26","key":"11_CR25","doi-asserted-by":"publisher","first-page":"2906","DOI":"10.1182\/blood-2017-09-804658","volume":"131","author":"MS Topp","year":"2018","unstructured":"Topp MS, Zimmerman Z, Cannell P, Dombret H, Maertens J, Stein A, Franklin J, Tran Q, Cong Z, Schuh AC (2018) Health related quality of life in adults with relapsed\/refractory acute lymphoblastic leukemia treated with blinatumomab. Blood 131(26):2906\u20132914","journal-title":"Blood"},{"key":"11_CR26","doi-asserted-by":"crossref","unstructured":"Pulte ED, Vallejo J, Przepiorka D, Nie L, Farrell AT, Goldberg KB, McKee AE, Pazdur R (2018) FDA supplemental approval: blinatumomab for treatment of relapsed and refractory precursor B-cell acute lymphoblastic leukemia. Oncologist 23(11):1366\u20131371","DOI":"10.1634\/theoncologist.2018-0179"},{"key":"11_CR27","doi-asserted-by":"crossref","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, ToppMS, FieldingAK,Rambaldi A, Ritchie EK, Papayannidis C, Sterling LR, Benjamin J, Stein A (2017) Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 35(16):1795\u20131802","DOI":"10.1200\/JCO.2016.69.3531"},{"key":"11_CR28","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1200\/JCO.2016.69.3531","volume":"35","author":"G Martinelli","year":"2017","unstructured":"Martinelli G, Boissel N, Chevallier P, Ottmann O, G\u00f6kbuget N, Topp MS et al (2017) Complete hematologic and molecular response in adult patients with relapsed\/refractory Philadelphia chromosome\u2013positive B-precursor acute lymphoblastic leukemia following treatment with blinatumomab: results from a phase II, single-arm, multicenter study. J Clin Oncol 35:1795\u20131802","journal-title":"J Clin Oncol"},{"key":"11_CR29","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1080\/10428194.2020.1780583","volume":"61","author":"N G\u00f6kbuget","year":"2020","unstructured":"G\u00f6kbuget N, Zugmaier G, Dombret H, Stein A, Bonifacio M, Graux C et al (2020) Curative outcomes following blinatumomab in adults with minimal residual disease B cell precursor acute lymphoblastic leukemia. Leuk Lymphoma 61:2665\u20132673","journal-title":"Leuk Lymphoma"},{"key":"11_CR30","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C et al (2016) Phase I\/phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol 34:4381\u20134389","journal-title":"J Clin Oncol"},{"key":"11_CR31","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/ajh.24783","volume":"92","author":"I Aldoss","year":"2017","unstructured":"Aldoss I, Song J, Stiller T, Nguyen T, Palmer J, O\u2019Donnell M et al (2017) Correlates of resistance and relapse during blinatumomab therapy for relapsed\/refractory acute lymphoblastic leukemia. Am J Hematol 92:858\u2013865","journal-title":"Am J Hematol"},{"key":"11_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1182\/blood.2020006287","volume":"137","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Aldoss I, Qu C, Crawford JC, Gu Z, Allen EK et al (2021) Tumor-intrinsic and -extrinsic determinants of response to blinatumomab in adults with BALL. Blood 137:471\u2013484","journal-title":"Blood"},{"key":"11_CR33","doi-asserted-by":"publisher","first-page":"5079","DOI":"10.1182\/blood-2019-122745","volume":"134","author":"AC King","year":"2019","unstructured":"King AC, Bolanos R, Velasco K, Tu H, Zaman F, Geyer MB et al (2019) Real world chart review of blinatumomab to treat patients with high disease burden of relapsed or refractory B cell precursor acute lymphoblastic leukemia. Blood 134:5079","journal-title":"Blood"},{"key":"11_CR34","first-page":"e36","volume":"188","author":"P Brown","year":"2019","unstructured":"Brown P, Zugmaier G, Gore L, Tuglus CA, Stackelberg A (2019) Day 15 bone marrow minimal residual disease predicts response to blinatumomab in relapsed\/refractory pediatric B-ALL. Brit J Haematol. 188:e36\u2013e39","journal-title":"Brit J Haematol."},{"key":"11_CR35","doi-asserted-by":"publisher","first-page":"e132","DOI":"10.3324\/haematol.2016.153957","volume":"102","author":"N G\u00f6kbuget","year":"2017","unstructured":"G\u00f6kbuget N, Zugmaier G, Klinger M, Kufer P, Stelljes M, Viardot A et al (2017) Long-term relapse-free survival in a phase 2 study of blinatumomab for the treatment of patients with minimal residual disease in B-lineage acute lymphoblastic leukemia. Haematologica 102:e132\u2013e135","journal-title":"Haematologica"},{"key":"11_CR36","doi-asserted-by":"publisher","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","volume":"32","author":"MS Topp","year":"2014","unstructured":"Topp MS, G\u00f6kbuget N, Zugmaier G, Klappers P, Stelljes M, Neumann S et al (2014) Phase II trial of the anti-CD19 bispecific T cell\u2013engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 32:4134\u20134140","journal-title":"J Clin Oncol"},{"key":"11_CR37","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1186\/s12885-019-6056-8","volume":"19","author":"M Kujawski","year":"2019","unstructured":"Kujawski M, Li L, Bhattacharya S, Wong P, Lee W-H et al (2019) Generation of dual specific bivalent BiTEs (dbBIspecific T cell engaging antibodies) for cellular immunotherapy. BMC Cancer 19:882","journal-title":"BMC Cancer"},{"key":"11_CR38","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1080\/10428194.2020.1759055","volume":"61","author":"L Coyle","year":"2020","unstructured":"Coyle L, Morley NJ, Rambaldi A, Mason KD, Verhoef G, Furness CL et al (2020) Open-label, phase 2 study of blinatumomab as second salvage therapy in adults with relapsed\/refractory aggressive B cell non-Hodgkin lymphoma. Leuk Lymphoma 61:2103\u20132112","journal-title":"Leuk Lymphoma"},{"key":"11_CR39","doi-asserted-by":"publisher","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","volume":"127","author":"A Viardot","year":"2016","unstructured":"Viardot A, Goebeler M, Hess G, Neumann S, Pfreundschuh M, Adrian N et al (2016) Phase 2 study of the bispecific T cell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuse large B cell lymphoma. Blood 127:1410\u20131416","journal-title":"Blood"},{"key":"11_CR40","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","volume":"124","author":"DW Lee","year":"2014","unstructured":"Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M et al (2014) Current concepts in the diagnosis and management of cytokine release syndrome. Blood 124:188\u2013195. https:\/\/doi.org\/10.1182\/blood-2014-05-552729","journal-title":"Blood"},{"key":"11_CR41","doi-asserted-by":"crossref","unstructured":"Li J, Piskol R, Ybarra R, Chen Y-JJ, Li J, Slaga D et al (2019) CD3 bispecific antibody induced cytokine release is dispensable for cytotoxic T cell activity. Sci Transl Med 11:eaax8861","DOI":"10.1126\/scitranslmed.aax8861"},{"key":"11_CR42","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/MOP.0000000000000043","volume":"26","author":"DM Barrett","year":"2014","unstructured":"Barrett DM, Teachey DT, Grupp SA (2014) Toxicity management for patients receiving novel T cell engaging therapies. Curr Opin Pediatr 26:43\u201349","journal-title":"Curr Opin Pediatr"},{"key":"11_CR43","doi-asserted-by":"crossref","unstructured":"Shimabukuro-Vornhagen A, Godel P, Subklewe M, Stemmler HJ, Schlosser HA, Schlaak M et al (2018) Cytokine release syndrome. J Immunother Cancer 6:56","DOI":"10.1186\/s40425-018-0343-9"},{"key":"11_CR44","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1007\/s00262-007-0298-z","volume":"56","author":"C Brandl","year":"2007","unstructured":"Brandl C, Haas C, d\u2019Argouges S, Fisch T, Kufer P, Brischwein K et al (2007) The effect of dexamethasone on polyclonal T cell activation and redirected target cell lysis as induced by a CD19\/CD3-bispecific single-chain antibody construct. Cancer Immunol Immunother 56:1551\u20131563","journal-title":"Cancer Immunol Immunother"},{"key":"11_CR45","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","volume":"31","author":"A Seckinger","year":"2017","unstructured":"Seckinger A, Delgado JA, Moser S, Moreno L, Neuber B, Grab A et al (2017) Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell 31:396\u2013410","journal-title":"Cancer Cell"},{"issue":"Suppl. 1","key":"11_CR46","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1182\/blood-2019-122895","volume":"134","author":"LJ Costa","year":"2019","unstructured":"Costa LJ, Wong SW, Berm\u00fadez A, de la Rubia J, Mateos M-V, Ocio EM et al (2019) First clinical study of the B cell maturation antigen (BCMA) 2+1 T cell engager (TCE) CC-93269 in patients (Pts) with relapsed\/refractory multiple myeloma (RRMM): interim results of a phase 1 multicenter trial. Blood 134(Suppl. 1):143","journal-title":"Blood"},{"key":"11_CR47","doi-asserted-by":"crossref","unstructured":"Wei AH, Ribera J-M, Larson RA, Ritchie D, Ghobadi A (2021) Biomarkers associated with blinatumomab outcomes in acute lymphoblastic leukemia. Leukemia 35:2220\u20132231","DOI":"10.1038\/s41375-020-01089-x"},{"key":"11_CR48","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1158\/1535-7163.MCT-19-0007","volume":"18","author":"SH Panowski","year":"2019","unstructured":"Panowski SH, Kuo TC, Zhang Y, Chen A, Geng T, Aschenbrenner L et al (2019) Preclinical efficacy and safety comparison of CD3 bispecific and ADC modalities targeting BCMA for the treatment of multiple myeloma. Mol Cancer Ther 18:2008\u20132020","journal-title":"Mol Cancer Ther"},{"key":"11_CR49","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-019-0703-z","volume":"12","author":"D Liu","year":"2019","unstructured":"Liu D, Zhao J, Song Y, Luo X, Yang T (2019) Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia. J Hematol Oncol 12:15","journal-title":"J Hematol Oncol"},{"key":"11_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-020-00342-x","volume":"10","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Zugmaier G, Mergen N, Bader P, Jeha S, Schlegel P et al (2020) Blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia: results of the RIALTO trial, an expanded access study. Blood Cancer J 10:1\u20135","journal-title":"Blood Cancer J"},{"key":"11_CR51","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","volume":"34","author":"M Goebeler","year":"2016","unstructured":"Goebeler M, Knop S, Viardot A, Kufer P, Topp MS, Einsele H et al (2016) Bispecific T cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed\/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol 34:1104\u20131111","journal-title":"J Clin Oncol"},{"issue":"13","key":"11_CR52","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1182\/bloodadvances.2018019034","volume":"2","author":"AS Stein","year":"2018","unstructured":"Stein AS, Larson RA, Schuh AC, StevensonW L-M, Tran Q, Zimmerman Z, KormanyW TMS (2018) Exposure adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia. Blood Adv 2(13):1522\u20131531","journal-title":"Blood Adv"},{"key":"11_CR53","doi-asserted-by":"crossref","unstructured":"Frey N, Porter D (2016) Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematol Am Soc Hematol Educ Program 2016(1):567\u2013572","DOI":"10.1182\/asheducation-2016.1.567"},{"issue":"36","key":"11_CR54","doi-asserted-by":"publisher","first-page":"4381","DOI":"10.1200\/JCO.2016.67.3301","volume":"34","author":"A von Stackelberg","year":"2016","unstructured":"von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O\u2019Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, Barnette P, Messina C, Michel G, DuBois SG, Hu K, ZhuM WJA, Gore L (2016) Phase I\/Phase II study of blinatumomab in pediatric patients with relapsed\/refractory acute lymphoblastic leukemia. J Clin Oncol 34(36):4381\u20134389","journal-title":"J Clin Oncol"},{"key":"11_CR55","doi-asserted-by":"crossref","unstructured":"Jain T, Litzow MR (2018) No free rides: management of toxicities of novel immunotherapies in ALL, including financial. Blood Adv 2(22):3393\u20133403","DOI":"10.1182\/bloodadvances.2018020198"},{"key":"11_CR56","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1158\/0008-5472.CAN-19-1131","volume":"80","author":"M Klinger","year":"2020","unstructured":"Klinger M, Zugmaier G, N\u00e4gele V, Goebeler M, Brandl C, Stelljes M et al (2020) Adhesion of T cells to endothelial cells facilitates blinatumomab-associated neurologic adverse events. Cancer Res 80:91\u2013101","journal-title":"Cancer Res"},{"key":"11_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1182\/blood-2020-135818","volume":"136","author":"MJ Matasar","year":"2020","unstructured":"Matasar MJ, Cheah CY, Yoon DH, Assouline SE, Bartlett NL, Ku M et al (2020) Subcutaneous mosunetuzumab in relapsed or refractory B cell lymphoma: promising safety and encouraging efficacy in dose escalation cohorts. Blood 136:45\u201346","journal-title":"Blood"},{"key":"11_CR58","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1182\/blood-2020-133355","volume":"136","author":"AM Lesokhin","year":"2020","unstructured":"Lesokhin AM, Levy MY, Dalovisio AP, Bahlis NJ, Solh M, Sebag M et al (2020) Preliminary safety, efficacy, pharmacokinetics, and pharmacodynamics of subcutaneously (SC) administered PF-06863135, a B cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM). Blood 136:8\u20139","journal-title":"Blood"},{"key":"11_CR59","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","volume":"359","author":"A Ribas","year":"2018","unstructured":"Ribas A, Wolchok JD (2018) Cancer immunotherapy using checkpoint blockade. Science 359:1350\u20131355","journal-title":"Science"},{"key":"11_CR60","doi-asserted-by":"publisher","first-page":"76902","DOI":"10.18632\/oncotarget.12357","volume":"7","author":"J Feucht","year":"2016","unstructured":"Feucht J, Kayser S, Gorodezki D, Hamieh M, D\u00f6ring M, Blaeschke F et al (2016) Tcell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T cell engager (BiTE) are regulated contrarily by PDL1 and CD80\/CD86 on leukemic blasts. Oncotarget 7:76902\u201376919","journal-title":"Oncotarget"},{"key":"11_CR61","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A et al (2017) Frequency of regulatory T cells determines the outcome of the T-cell engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia 31:2181\u20132190","journal-title":"Leukemia"},{"key":"11_CR62","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1002\/eji.200324181","volume":"34","author":"F Ghiringhelli","year":"2004","unstructured":"Ghiringhelli F, Larmonier N, Schmitt E, Parcellier A, Cathelin D, Garrido C et al (2004) CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 34:336\u2013344","journal-title":"Eur J Immunol"},{"key":"11_CR63","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/ajh.24987","volume":"93","author":"E Jabbour","year":"2018","unstructured":"Jabbour E, D\u00fcll J, Yilmaz M, Khoury JD, Ravandi F, Jain N et al (2018) Outcome of patients with relapsed\/refractory acute lymphoblastic leukemia after blinatumomab failure: no change in the level of CD19 expression. Am J Hematol 93:371\u2013374","journal-title":"Am J Hematol"},{"key":"11_CR64","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1182\/blood-2016-05-718395","volume":"129","author":"F Braig","year":"2017","unstructured":"Braig F, Brandt A, Goebeler M, Tony H, Kurze A, Nollau P et al (2017) Resistance to anti-CD19\/CD3 BiTE in acute lymphoblastic leukemia may be mediated by disrupted CD19 membrane trafficking. Blood 129:100\u2013104","journal-title":"Blood"},{"key":"11_CR65","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","volume":"127","author":"R Gardner","year":"2016","unstructured":"Gardner R, Wu D, Cherian S, Fang M, Hanafi L, Finney O et al (2016) Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL rearranged B-ALL from CD19 CAR-T-cell therapy. Blood 127:2406\u20132410","journal-title":"Blood"},{"key":"11_CR66","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1002\/pbc.25953","volume":"63","author":"A Rayes","year":"2016","unstructured":"Rayes A, McMasters RL, O\u2019Brien MM (2016) Lineage switch in MLL-rearranged infant leukemia following CD19-directed therapy. Pediatr Blood Cancer 63:1113\u20131115","journal-title":"Pediatr Blood Cancer"},{"key":"11_CR67","doi-asserted-by":"publisher","first-page":"3814","DOI":"10.1172\/JCI87366","volume":"126","author":"M Ruella","year":"2016","unstructured":"Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J et al (2016) Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest 126:3814\u20133826","journal-title":"J Clin Invest"},{"key":"11_CR68","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13045-020-00856-8","volume":"13","author":"H Dai","year":"2020","unstructured":"Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D et al (2020) Bispecific CAR-T cells targeting both CD19 and CD22 for therapy of adults with relapsed or refractory B cell acute lymphoblastic leukemia. J Hematol Oncol 13:30","journal-title":"J Hematol Oncol"},{"key":"11_CR69","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1158\/0008-5472.CAN-11-1620","volume":"72","author":"S-R Woo","year":"2012","unstructured":"Woo S-R, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ et al (2012) Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Res 72:917\u2013927","journal-title":"Cancer Res"},{"key":"11_CR70","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/j.ccell.2014.10.018","volume":"26","author":"RJ Johnston","year":"2014","unstructured":"Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y et al (2014) The immunoreceptor TIGIT regulates anti-tumor and antiviral CD8(+) T cell effector function. Cancer Cell 26:923\u2013937","journal-title":"Cancer Cell"},{"key":"11_CR71","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature05115","volume":"443","author":"CL Day","year":"2006","unstructured":"Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S et al (2006) PD-1 expression on HIV-specific T cells is associated with T cell exhaustion and disease progression. Nature 443:350\u2013354","journal-title":"Nature"},{"key":"11_CR72","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.csbj.2016.09.003","volume":"14","author":"M Ruella","year":"2016","unstructured":"Ruella M, Maus MV (2016) Catch me if you can: leukemia escape after CD19-directed T cell immunotherapies. Comput Struct Biotechnol J 14:357\u2013362","journal-title":"Comput Struct Biotechnol J"},{"key":"11_CR73","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/leu.2013.243","volume":"28","author":"C Arndt","year":"2014","unstructured":"Arndt C, Feldmann A, von Bonin M, Cartellieri M, Ewen E-M, Koristka S et al (2014) Costimulation improves the killing capability of T cells redirected to tumor cells expressing low levels of CD33: description of a novel modular targeting system. Leukemia 28:59\u201369","journal-title":"Leukemia"},{"key":"11_CR74","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1097\/CJI.0b013e3181d75c20","volume":"33","author":"R Liu","year":"2010","unstructured":"Liu R, Jiang W, Yang M, Guo H, Zhang Y, Wang J et al (2010) Efficient inhibition of human B cell lymphoma in SCID mice by synergistic anti-tumor effect of human 4\u20131BB ligand\/anti-CD20 fusion proteins and anti-CD3\/anti-CD20 diabodies. J Immunother 33:500\u2013509","journal-title":"J Immunother"},{"key":"11_CR75","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.4143\/crt.2016.491","volume":"49","author":"JU Schmohl","year":"2017","unstructured":"Schmohl JU, Felices M, Oh F, Lenvik AJ, Lebeau AM, Panyam J et al (2017) Engineering of Anti-CD133 trispecific molecule capable of inducing NK expansion and driving antibody-dependent cell-mediated cytotoxicity. Cancer Res Treat 49:1140\u20131152","journal-title":"Cancer Res Treat"},{"key":"11_CR76","unstructured":"Khan S, Gerber DE (2019) Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: a review. Semin Cancer Biol S1044-579X(19)30019-7"},{"key":"11_CR77","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1038\/leu.2017.41","volume":"31","author":"J Duell","year":"2017","unstructured":"Duell J, Dittrich M, Bedke T, Mueller T, Eisele F, Rosenwald A et al (2017) Frequency of regulatory T cells determines the outcome of the T cell engaging antibody blinatumomab in patients with B-precursor ALL. Leukemia 31:2181\u20132190","journal-title":"Leukemia"},{"key":"11_CR78","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1182\/blood.V128.22.621.621","volume":"128","author":"R Bannerji","year":"2016","unstructured":"Bannerji R, Brown JR, Advani RH, Arnason J, O\u2019Brien SM, Allan JN et al (2016) Phase 1 study of REGN1979, an anti-CD20 x anti-CD3 bispecific monoclonal antibody, in patients with CD20+ B cell malignancies previously treated with CD20-directed antibody therapy. Blood 128:621","journal-title":"Blood"},{"issue":"Suppl. 1","key":"11_CR79","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2019-123742","volume":"134","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bartlett NL, Assouline S, Yoon S-S, Bosch F, Sehn LH et al (2019) Mosunetuzumab induces complete remissions in poor prognosis Non-Hodgkin lymphoma patients, including those who are resistant to or relapsing after chimeric antigen receptor T cell (CAR-T) therapies, and is active in treatment through multiple lines. Blood 134(Suppl. 1):6","journal-title":"Blood"},{"key":"11_CR80","first-page":"728","volume":"6","author":"U Reusch","year":"2014","unstructured":"Reusch U, Burkhardt C, Fucek I, Le Gall F, Le Gall M, Hoffmann K et al (2014) A novel tetravalent bispecific TandAb (CD30\/CD16A) efficiently recruits NK cells for the lysis of CD30+ tumor cells. MAbs 6:728\u2013739","journal-title":"MAbs"},{"key":"11_CR81","doi-asserted-by":"publisher","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","volume":"24","author":"M Bacac","year":"2018","unstructured":"Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S et al (2018) CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies. Clin Cancer Res 24:4785\u20134797","journal-title":"Clin Cancer Res"},{"key":"11_CR82","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s11899-018-0472-8","volume":"13","author":"DG Guy","year":"2018","unstructured":"Guy DG, Uy GL (2018) Bispecific antibodies for the treatment of acute myeloid leukemia. Curr Hematol Malig Rep 13:417\u2013425","journal-title":"Curr Hematol Malig Rep"},{"issue":"4","key":"11_CR83","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1182\/blood.V67.4.1048.1048","volume":"67","author":"PA Dinndorf","year":"1986","unstructured":"Dinndorf PA, Andrews RG, Benjamin D, Ridgway D, Wolff L, Bernstein ID (1986) Expression of normal myeloid-associated antigens by acute leukemia cells. Blood 67(4):1048\u20131053","journal-title":"Blood"},{"key":"11_CR84","doi-asserted-by":"crossref","unstructured":"Hauswirth AW, Florian S, Printz D, Sotlar K, KrauthMT, Fritsch G et al (2007) Expression of the target receptor CD33 in CD34+\/CD38-\/CD123+ AML stem cells. Eur J Clin Inv 37(1):73\u201382","DOI":"10.1111\/j.1365-2362.2007.01746.x"},{"issue":"3","key":"11_CR85","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1182\/blood-2013-08-523548","volume":"123","author":"C Krupka","year":"2014","unstructured":"Krupka C, Kufer P, Kischel R, Zugmaier G, Bogeholz J, Kohnke T et al (2014) CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T cell-engaging antibody AMG 330. Blood 123(3):356\u2013365","journal-title":"Blood"},{"issue":"3","key":"11_CR86","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.molimm.2011.09.019","volume":"49","author":"S Stamova","year":"2011","unstructured":"Stamova S, Cartellieri M, Feldmann A, Arndt C, Koristka S, Bartsch H et al (2011) Unexpected recombinations in single-chain bispecific anti-CD3-anti-CD33 antibodies can be avoided by a novel linker module. Mol Immunol 49(3):474\u2013482","journal-title":"Mol Immunol"},{"issue":"4","key":"11_CR87","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1038\/leu.2013.18","volume":"27","author":"C Arndt","year":"2013","unstructured":"Arndt C, von Bonin M, Cartellieri M, Feldmann A, Koristka S, Michalk I et al (2013) Redirection of T cells with a first fully humanized bispecific CD33-CD3 antibody efficiently eliminates AML blasts without harming hematopoietic stem cells. Leukemia 27(4):964\u2013967","journal-title":"Leukemia"},{"key":"11_CR88","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nri2056","volume":"7","author":"PR Crocker","year":"2007","unstructured":"Crocker PR, Paulson JC, Varki A (2007) Siglecs and their roles in the immune system. Nat Rev Immunol 7:255\u2013266","journal-title":"Nat Rev Immunol"},{"key":"11_CR89","doi-asserted-by":"publisher","first-page":"7508","DOI":"10.1200\/JCO.2020.38.15_suppl.7508","volume":"38","author":"F Ravandi","year":"2020","unstructured":"Ravandi F, Walter RB, Subklewe M, Buecklein V, Jongen-Lavrencic M, Paschka P et al (2020) Updated results from phase I dose-escalation study of AMG 330, a bispecific T cell engager molecule, in patients with relapsed\/refractory acute myeloid leukemia (R\/R AML). J Clin Oncol 38:7508","journal-title":"J Clin Oncol"},{"issue":"21","key":"11_CR90","doi-asserted-by":"publisher","first-page":"2532","DOI":"10.1038\/sj.onc.1203594","volume":"19","author":"EP Reddy","year":"2000","unstructured":"Reddy EP, Korapati A, Chaturvedi P, Rane S (2000) IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled. Oncogene 19(21):2532\u20132547","journal-title":"Oncogene"},{"key":"11_CR91","doi-asserted-by":"crossref","unstructured":"BlalockWL,Weinstein-Oppenheimer C, Chang F, Hoyle PE, Wang XY, Algate PA et al (1999) Signal transduction, cell cycle regulatory, and anti-apoptotic pathways regulated by IL-3 in hematopoietic cells: possible sites for intervention with anti-neoplastic drugs. Leukemia 13(8):1109\u20131166","DOI":"10.1038\/sj.leu.2401493"},{"issue":"22","key":"11_CR92","doi-asserted-by":"publisher","first-page":"2824","DOI":"10.1182\/blood.V128.22.2824.2824","volume":"128","author":"FNJ Gaudet","year":"2016","unstructured":"Gaudet FNJ et al (2016) Development of a CD123xCD3 bispecific antibody (JNJ-63709178) for the treatment of acute myeloid leukemia (AML). Blood 128(22):2824","journal-title":"Blood"},{"issue":"21","key":"11_CR93","doi-asserted-by":"publisher","first-page":"2316","DOI":"10.1182\/blood.V124.21.2316.2316","volume":"124","author":"SY Chu","year":"2014","unstructured":"Chu SY, Pong E, Chen H, Phung S, Chan EW, Endo NA et al (2014) Immunotherapy with long-lived anti-CD123 \u00d7 anti-CD3 bispecific antibodies stimulates potent Tcell-mediated killing of human AML cell lines and of CD123+ cells in monkeys: a potential therapy for acute myelogenous leukemia. Blood 124(21):2316","journal-title":"Blood"},{"issue":"4","key":"11_CR94","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1182\/blood-2004-08-2997","volume":"105","author":"AD Billiau","year":"2005","unstructured":"Billiau AD, Roskams T, Van Damme-Lombaerts R, Matthys P, Wouters C (2005) Macrophage activation syndrome: characteristic findings on liver biopsy illustrating the key role of activated, IFN-g producing lymphocytes and IL-6- and TNF-alpha-producing macrophages. Blood 105(4):1648\u20131651","journal-title":"Blood"},{"key":"11_CR95","doi-asserted-by":"crossref","unstructured":"Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6(224):224ra25","DOI":"10.1126\/scitranslmed.3008226"},{"issue":"9967","key":"11_CR96","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","volume":"385","author":"DW Lee","year":"2015","unstructured":"Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA et al (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukemia in children and young adults: a phase 1 dose-escalation trial. Lancet (London, England). 385(9967):517\u2013528","journal-title":"Lancet (London, England)."},{"issue":"16","key":"11_CR97","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","volume":"371","author":"SL Maude","year":"2014","unstructured":"Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ et al (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507\u20131517","journal-title":"N Engl J Med"},{"key":"11_CR98","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1200\/JCO.19.02657","volume":"38","author":"MS Topp","year":"2020","unstructured":"Topp MS, Duell J, Zugmaier G, Attal M, Moreau P, Langer C et al (2020) Anti-B cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma. J Clin Oncol 38:775\u2013783","journal-title":"J Clin Oncol"},{"key":"11_CR99","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1038\/leu.2016.388","volume":"31","author":"S Hipp","year":"2017","unstructured":"Hipp S, Tai Y-T, Blanset D, Deegen P, Wahl J, Thomas O et al (2017) A novel BCMA\/CD3 bispecific T cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo. Leukemia 31:1743\u20131751","journal-title":"Leukemia"},{"key":"11_CR100","doi-asserted-by":"crossref","unstructured":"Zuch de Zafra CL, Fajardo F, Zhong W, Bernett MJ, Muchhal US, Moore GL et al (2019) Targeting multiple myeloma with AMG 424, a novel Anti-CD38\/CD3 bispecific t cell-recruiting antibody optimized for cytotoxicity and cytokine release. Clin Cancer Res 25:3921\u20133933","DOI":"10.1158\/1078-0432.CCR-18-2752"},{"issue":"Suppl. 1","key":"11_CR101","doi-asserted-by":"publisher","first-page":"3229","DOI":"10.1182\/blood-2018-99-110427","volume":"132","author":"AM Lesokhin","year":"2018","unstructured":"Lesokhin AM, Raje N, Gasparetto CJ, Walker J, Krupka HI, Joh T et al (2018) A phase I, open-label study to evaluate the safety, pharmacokinetic, pharmacodynamic, and clinical activity of PF-06863135, a B cell maturation antigen\/CD3 bispecific antibody, in patients with relapsed\/refractory advanced multiple myeloma. Blood 132(Suppl. 1):3229","journal-title":"Blood"},{"key":"11_CR102","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1093\/intimm\/dxl069","volume":"18","author":"AG Polson","year":"2006","unstructured":"Polson AG, Zheng B, Elkins K, Chang W, Du C, Dowd P et al (2006) Expression pattern of the human FcRH\/IRTA receptors in normal tissue and in B-chronic lymphocytic leukemia. Int Immunol 18:1363\u20131373","journal-title":"Int Immunol"},{"key":"11_CR103","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/sj.leu.2404445","volume":"21","author":"T Ise","year":"2007","unstructured":"Ise T, Nagata S, Kreitman RJ, Wilson WH, Wayne AS, Stetler-Stevenson M et al (2007) Elevation of soluble CD307 (IRTA2\/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia 21:169\u2013174","journal-title":"Leukemia"},{"key":"11_CR104","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1158\/1535-7163.MCT-18-1216","volume":"18","author":"T Kodama","year":"2019","unstructured":"Kodama T, Kochi Y, Nakai W, Mizuno H, Baba T, Habu K et al (2019) Anti-GPRC5D\/CD3 bispecific T cell redirecting antibody for the treatment of multiple myeloma. Mol Cancer Ther 18:1555\u20131564","journal-title":"Mol Cancer Ther"},{"key":"11_CR105","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/j.1365-2362.2012.02679.x","volume":"42","author":"J Atamaniuk","year":"2012","unstructured":"Atamaniuk J, Gleiss A, Porpaczy E, Kainz B, Grunt TW, Raderer M et al (2012) Overexpression of G protein-coupled receptor 5D in the bone marrow is associated with poor prognosis in patients with multiple myeloma. Eur J Clin Invest 42:953\u2013960","journal-title":"Eur J Clin Invest"},{"key":"11_CR106","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.ccell.2017.02.001","volume":"31","author":"J Li","year":"2017","unstructured":"Li J, Stagg NJ, Johnston J, Harris MJ, Menzies SA, DiCara D et al (2017) Membrane proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing. Cancer Cell 31:383\u2013395","journal-title":"Cancer Cell"},{"key":"11_CR107","doi-asserted-by":"crossref","unstructured":"Viardot A, Goebeler ME, Hess G, Neumann S, Pfreundschuh M, Adrian N et al (2016) Phase 2 study of the bispecific Tcell engager (BiTE) antibody blinatumomab in relapsed\/refractory diffuselarge B-cell lymphoma. Blood 127:1410\u20136","DOI":"10.1182\/blood-2015-06-651380"},{"key":"11_CR108","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/1574884713666180518102514","volume":"13","author":"Y Hijazi","year":"2018","unstructured":"Hijazi Y, Klinger M, Kratzer A, Wu B, Baeuerle PA et al (2018) Pharmacokinetic and pharmacodynamic relationship of blinatumomab in patients with non-hodgkin lymphoma. Curr Clin Pharm 13:55\u201364","journal-title":"Curr Clin Pharm"},{"key":"11_CR109","doi-asserted-by":"crossref","unstructured":"Liu L, Lam C-YK, Long V, Widjaja L, Yang Y, Li H et al (2017) MGD011, A CD19 x CD3 dual-affinity retargeting bi-specific molecule incorporating extended circulating half-life for the treatment of B cell malignancies. Clin Cancer Res 23:1506\u20131518","DOI":"10.1158\/1078-0432.CCR-16-0666"},{"key":"11_CR110","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1080\/19420862.2015.1029216","volume":"7","author":"U Reusch","year":"2015","unstructured":"Reusch U, Duell J, Ellwanger K, Herbrecht C, Knackmuss SH, Fucek I et al (2015) A tetravalent bispecific TandAb (CD19\/CD3), AFM11, efficiently recruits T cells for the potent lysis of CD19(+) tumor cells. MAbs 7:584\u2013604","journal-title":"MAbs"},{"issue":"23","key":"11_CR111","doi-asserted-by":"publisher","first-page":"5829","DOI":"10.1158\/1078-0432.CCR-16-0350","volume":"22","author":"U Reusch","year":"2016","unstructured":"Reusch U, Harrington KH, Gudgeon CJ, Fucek I, Ellwanger K, Weichel M et al (2016) Characterization of CD33\/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia. Clin Cancer Res 22(23):5829\u20135838","journal-title":"Clin Cancer Res"},{"key":"11_CR112","doi-asserted-by":"crossref","unstructured":"Westervelt P, Roboz, GJ et al (2018) Phase 1 first-in-human trial of AMV564, a bivalent bispecific (2x2) CD33\/CD3 T cell engager, in patients with relapsed\/refractory acute myeloid leukemia (AML). Presented at the 23rd Congress of the European Hematology Association (EHA), 14\u201317 June 2018, Stockholm, Sweden","DOI":"10.1182\/blood-2018-99-111529"},{"key":"11_CR113","doi-asserted-by":"publisher","first-page":"76902","DOI":"10.18632\/oncotarget.12357","volume":"7","author":"J Feucht","year":"2016","unstructured":"Feucht J, Kayser S, Gorodezki D, Hamieh M, Doring M, Blaeschke F et al (2016) T cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T cell engager (BiTE) are regulated contrarily by PDL1 and CD80\/CD86 on leukemic blasts. Oncotarget 7:76902\u201376919","journal-title":"Oncotarget"},{"issue":"13 Suppl.","key":"11_CR114","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1158\/1538-7445.AM2018-2776","volume":"78","author":"SJ Dovedi","year":"2018","unstructured":"Dovedi SJ, Mazor Y, Elder M, Hasani S, Wang B, Mosely S et al (2018) Abstract 2776: MEDI5752: a novel bispecific antibody that preferentially targets CTLA-4 on PD-1 expressing T cells. Cancer Res 78(13 Suppl.):2776","journal-title":"Cancer Res"},{"issue":"Suppl. 1","key":"11_CR115","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1182\/blood-2018-99-111845","volume":"132","author":"J Webster","year":"2018","unstructured":"Webster J, Luskin MR, Prince GT, DeZern AE, DeAngelo DJ, Levis MJ, Blackford A, Sharon E, Streicher H, Luznik L, Gojo I (2018) Blinatumomab in combination with immune checkpoint inhibitors of PD-1 and CTLA-4 in adult patients with relapsed\/refractory (R\/R) CD19 positive B cell acute lymphoblastic leukemia (ALL): preliminary results of a phase I study. Blood 132(Suppl. 1):557","journal-title":"Blood"},{"key":"11_CR116","doi-asserted-by":"crossref","unstructured":"Schwartz MS, Jeyakumar D, Damon LE, Schiller GJ, Wieduwilt MJ (2019) A phase I\/II study of blinatumomab in combination with pembrolizumab for adults with relapsed refractory B-lineage acute lymphoblastic leukemia: University of California Hematologic Malignancies Consortium Study 1504. J Clin Oncol 37(15_suppl):TPS7064","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS7064"},{"issue":"12","key":"11_CR117","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1016\/j.clml.2017.08.101","volume":"17","author":"R Assi","year":"2017","unstructured":"Assi R, Kantarjian H, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo C, Burger J, Cortes J, Jain N, Wierda W, Chamoun S, Konopleva M, Jabbour E (2017) Safety and efficacy of blinatumomab in combination with a tyrosine kinase inhibitor for the treatment of relapsed Philadelphia chromosome-positive leukemia. Clin Lymphoma Myeloma Leuk 17(12):897\u2013901","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"11_CR118","doi-asserted-by":"crossref","unstructured":"Usmani SZ et al (2021) Teclistamab, a B cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicenter, open label, single-arm, phase 1 study. Lancet","DOI":"10.1016\/S0140-6736(21)01338-6"},{"key":"11_CR119","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1186\/s13045-021-01084-4","volume":"14","author":"Z Tian","year":"2021","unstructured":"Tian Z, Liu M, Zhang Y, Wan X (2021) Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol 14:75","journal-title":"J Hematol Oncol"}],"container-title":["Cancer Treatment and Research","Cancer Immunotherapies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-030-96376-7_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,4]],"date-time":"2023-02-04T23:57:25Z","timestamp":1675555045000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-030-96376-7_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9783030963750","9783030963767"],"references-count":119,"URL":"https:\/\/doi.org\/10.1007\/978-3-030-96376-7_11","relation":{},"ISSN":["0927-3042","2509-8497"],"issn-type":[{"value":"0927-3042","type":"print"},{"value":"2509-8497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"13 May 2022","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}